The Ministry of health and social development of the Republic of Kazakhstan approved the registration of well-known drug for the treatment of HIV "Trimec" (Triumeq), the correspondent Tengrinews.kz with reference to the company's GSK and ViiV Healthcare.
A drug intended for the treatment of HIV infection in adults and adolescents 12 years and older weighing at least 40 pounds. This drug is representative of a new class of antiretroviral therapy based on antivirals Dolutegravir, which gives patients the opportunity to take only one tablet once a day.
Tablet contains three components, namely a standard, long-used for the treatment of HIV, combination of drugs "abacavir/lamivudine", to which was added the drug of the new generation, "dolutegravir", an integrase inhibitor.
Experts say that before using medicine that contains abacavir, an HIV-infected patient was recommended to undergo screening for the presence of genetic marker alleles HLA-B*5701. Patients with identified genetic marker have a high predisposition for hypersensitivity to abacavir.